Bristol-Myers Squibb Company (BMY) Q1 2026 Earnings Call Transcript
Bristol-Myers Squibb Company reported its first-quarter 2026 earnings on April 30, 2026, revealing financial results that surpassed analyst expectations. The company achieved an EPS of $1.58 and revenue of $11.49 billion, reflecting a year-over-year increase of 2.57%. Executives and analysts discussed performance, strategy, and outlook during the earnings call, highlighting key developments in commercial operations and drug development.
- ▪Bristol-Myers Squibb reported Q1 2026 EPS of $1.58, beating estimates by $0.16.
- ▪The company's Q1 2026 revenue was $11.49 billion, exceeding forecasts by $571.70 million and rising 2.57% year-over-year.
- ▪Charles Triano served as SVP and Head of Investor Relations during the call.
- ▪Christopher Boerner is CEO and Chairman of Bristol-Myers Squibb Company.
- ▪David Elkins holds the position of Executive VP and CFO at Bristol-Myers Squibb.
Opening excerpt (first ~120 words) tap to expand
{"@context":"https://schema.org","@type":"NewsArticle","mainEntityOfPage":{"@type":"WebPage","@id":"https://seekingalpha.com/article/4896655-bristol-myers-squibb-company-bmy-q1-2026-earnings-call-transcript"},"author":{"@type":"Person","name":"SA Transcripts","url":"https://seekingalpha.com/author/sa-transcripts"},"publisher":{"@context":"http://schema.org","@type":"Organization","address":{"@type":"PostalAddress","streetAddress":"244 5th Ave","addressLocality":"New York","addressRegion":"NY","postalCode":"10001","addressCountry":"US"},"alternateName":["SeekingAlpha","SA"],"brand":[{"@type":"Brand","name":"Seeking Alpha Premium","url":"https://seekingalpha.com/subscriptions/premium"},{"@type":"Brand","name":"Seeking Alpha…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Seeking Alpha.
Discussion
0 commentsMore from Seeking Alpha
